A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)



Status:Active, not recruiting
Conditions:Hematology, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:8/2/2017
Start Date:October 2013

Use our guide to learn which trials are right for you!

This is a prospective study to collect blood and bone marrow samples from patients with SM
and MGUS. About 100 subjects will be enrolled at the University of Pennsylvania and followed
for 2 years. The primary objective of this study is to evaluate CMMCs as a biomarker to
detect patients at high risk of progression to multiple myeloma in patients with MGUS and
SMM.

The primary objective is to evaluate CMMCs as a biomarker to detect patients at high risk of
progression to multiple myeloma in patients with MGUS and SMM. The secondary objective are to
correlate CMMCs with the Mayo Clinic prognostic models in MGUS/SMM, to compare bone marrow
genomic findings with genomic findings in CMMC (utilizing multiple myeloma FISH panel), to
perform immunophenotyping of bone marrow plasma cells, to perform gene expression profiling
on CD138+bone marrow plasma cells and correlate with progression, to perform serum microRNA
profiling and correlate with progression, to correlate bone marrow immunohistochemical
studies evaluating the microenvironment with CMMC, to perform proteomic profiling on
peripheral blood to evaluate serum biomarkers of progression and to establish a biorepository
of samples of peripheral blood for future studies.

Inclusion Criteria:

- Age 18 or greater

- Capable of informed consent

- A monoclonal gammopathy detected in the serum, including intact immunoglobulin (IgG
and IgA) and light chain only gammopathies. Light chain only gammopathy is defined as
an abnormal light chain ratio and increased involved light chain).44, 45

- Absence of myeloma related organ or tissue impairment ("CRAB") as defined by:

- Hypercalcemia (calcium greater than or equal to 11)

- Renal failure (creatinine >2.0)

- Anemia hemoglobin <10 gm/dl)

- Bone disease (Osteolytic lesions, fractures)

Exclusion Criteria:

- A secondary B-cell neoplasm or other active malignancy aside from non-melanoma skin
cancer or localized prostate cancer. An active malignancy is any malignancy requiring
therapy within the past 3 years. Patients with monoclonal B-cell lymphocytosis are not
excluded.

- IgM monoclonal gammopathy

- Inability to comply with follow-up
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
(215) 662-6065
Principal Investigator: Brendan Weiss, MD
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials